Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis

Chin Med J (Engl). 2021 Sep 15;134(21):2629-2631. doi: 10.1097/CM9.0000000000001710.

Authors

Lin Cai¹, Jian-Zhong Zhang¹, Min Zheng², Shi-Fa Zhang³, Manmath Patekar⁴

Affiliations

¹ Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
² Department of Dermatology, Second Affiliated Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310.
³ Department of Dermatology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110016, China.
⁴ Novartis Pharma AG, Basel, Switzerland.

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized
Arthritis, Psoriatic* / drug therapy
China
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
secukinumab